TrialJournal of the European Academy of Dermatology and Venereology : JEADV2021

Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1.

W Cantrell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.